Core Insights - The new National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) and the first Commercial Health Insurance Innovative Drug Catalog (2025) will be implemented nationwide starting January 1, 2026, adding 114 new drugs to the basic insurance catalog and 19 to the commercial insurance catalog [1][6]. Summary by Sections Drug Inclusion and Coverage Expansion - The basic medical insurance catalog includes 114 new drugs, with 36 for cancer, 12 for chronic diseases like diabetes, 13 for anti-infection, and 10 for rare diseases, while 29 drugs were removed due to better alternatives [1]. - The total number of drugs in the national medical insurance catalog will increase to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines [1]. Innovation and Market Impact - The inclusion of 50 first-class innovative drugs reflects a significant increase in the success rate of new drug approvals to 88%, up from 76% in 2024, indicating a shift towards strategic and value-based purchasing in medical insurance [3][4]. - Notable foreign innovative products, such as Novartis' and Johnson & Johnson's drugs, have also been included, highlighting the commitment to enhancing drug accessibility [3]. Policy Measures for Drug Accessibility - To address the issue of newly included drugs not being available in hospitals, the policy mandates that medical institutions must include these drugs in their procurement lists by the end of February 2026 and allows for temporary green channels if necessary [2]. - Negotiated drugs will not be subject to administrative restrictions, ensuring better access for patients [2]. Commercial Health Insurance Innovations - The first commercial health insurance innovative drug catalog includes 19 drugs, focusing on high-innovation, clinically valuable treatments that exceed basic insurance coverage, thus addressing gaps in clinical drug availability [6]. - The drugs listed are primarily from the 2021-2025 period and include advanced therapies for rare diseases, enhancing market appeal and patient access [6]. Industry Response and Future Directions - The policy signals strong government support for independent innovation, encouraging pharmaceutical companies to invest more in original and differentiated research and development [7]. - The National Medical Insurance Bureau plans to refine policies and strengthen management to ensure the effective implementation of the new drug catalogs, ultimately improving public access to necessary medications [7].

Market Overview - The Hong Kong stock market experienced its strongest opening in nearly 13 years, with the Hang Seng Index rising by 707.93 points to close at 26,338.47, marking a 2.76% increase, the best performance since January 2, 2013 [1][23][27] - The Hang Seng Tech Index performed even better, closing at 5,736.44 points, up 220.46 points, a 4% increase [2][25] Sector Performance - All sectors showed positive performance, with semiconductors, defense, software services, and home appliances leading the gains [3][28] - Notable sector performances included: - Defense and military: 7.87% - Software services: 7.78% - Home appliances: 4.18% - Steel: 3.99% [4] Key Stocks - Within the tech sector, significant gains were observed in: - Hua Hong Semiconductor and Baidu Group, both rising over 9% - NetEase up over 6% - Trip.com up over 5% - SMIC and Li Auto both up over 4% - Major companies Alibaba and Tencent both up over 4% [4][26] Analyst Predictions - Analysts noted that the strong performance of the Hong Kong market was driven by local and foreign funds, despite the absence of southbound capital [5][27] - Predictions for the Hang Seng Index in 2026 include: - DBS Bank forecasts a target of 36,500 points in a bullish scenario, representing an increase of over 10,000 points from current levels [6][29] - Morgan Stanley sets a target of 34,700 points, with a projected P/E ratio of 13.4 times [7][30] - UBS anticipates a target of 30,000 points, driven by continued positive factors from 2025 [8][31] - HSBC predicts the index will reach 31,000 points, indicating a potential increase of about 21% [11][33] Investment Strategies - Analysts suggest a shift from "single-sided bets" to "balanced allocation" in investment strategies for 2026, focusing on AI hardware and high-dividend assets [12][34] - Key investment themes include: - Growth sectors such as AI applications, semiconductors, military technology, and innovative pharmaceuticals [15][37] - Dividend assets including insurance, utilities, and quality bank stocks [16][38] - Value discovery in traditional industry leaders like steel and machinery [17][39] Market Sentiment - The overall sentiment for the Hong Kong stock market remains optimistic, with expectations of continued upward trends supported by favorable domestic and international policies [21][43] - The market is expected to experience a second round of valuation recovery, driven by internal and external factors [18][40]

Core Viewpoint - The article highlights the impressive performance of the Rongtong Fund, particularly the Rongtong Industry Trend Fund, which achieved a net value increase of 114.61% in 2025, significantly outperforming its benchmark of 17.02% [1]. Group 1: Fund Performance - The Rongtong Industry Trend Fund ranked first among standard equity funds, with a specific ranking of 1 out of 349 [1]. - The Rongtong Industry Trend Fund Zhenxuan also doubled its performance, achieving a return of 100.22% in 2025 [1]. - The fund manager, Li Jin, has a strong background in technology and has been focusing on TMT and new energy sectors since joining Rongtong Fund [1]. Group 2: Investment Strategy - Li Jin's investment strategy is centered around identifying sectors with significant demand expansion and rapid industry growth, which he refers to as "investment with a sense of the times" [4]. - The fund's excess returns are attributed to investments in AI, new consumption, and innovative pharmaceuticals [4]. - Li Jin began focusing the investment portfolio on artificial intelligence in March 2023, recognizing its potential as a major technological advancement [4]. Group 3: Market Insights - Li Jin observed a rapid increase in the use of collagen-containing cosmetics, leading to a deeper investigation into the new consumption sector, which is experiencing significant growth [5]. - He also identified the innovative pharmaceutical sector as being in the early stages of a new wave of growth, prompting investment in this area [6]. - The combination of AI, new consumption, and innovative pharmaceuticals forms a strategic "trident" for the fund's investment approach [6]. Group 4: Future Outlook - For 2026, Li Jin anticipates a shift in the economic growth engine from monetary easing to credit expansion, which will support the recovery of the real economy [8]. - He expects corporate profitability to improve due to supply-side optimization and a rebalancing of supply and demand [8]. - Li Jin believes that the overall valuation of A-shares remains reasonable, predicting a transition from valuation-driven growth to a more balanced approach driven by fundamentals and structural reforms [8]. Group 5: Continued Focus Areas - Li Jin plans to maintain a focus on sectors with long-term growth potential, particularly in AI, which is still in a critical "infrastructure" phase [9]. - He emphasizes the importance of monitoring the demand for computing power and related technologies, which are expected to see continued growth [9]. - The strategy includes ongoing attention to opportunities in new energy, innovative pharmaceuticals, and new consumption, aiming to identify high-quality growth leaders in these sectors [9].

Core Insights - The public fund industry has shown a significant profit effect in 2025, with notable performance from the Rongtong Industrial Trend fund, which achieved a net value increase of 114.61%, far exceeding the benchmark of 17.02% [1] - Fund manager Li Jin has been pivotal in this success, focusing on sectors such as AI, new consumption, and innovative pharmaceuticals, which he refers to as a "sense of the times" investment strategy [2][3] Fund Performance - Rongtong Industrial Trend achieved a return of 114.61% in 2025, ranking first among 349 similar standard equity funds [1] - Rongtong Industrial Trend Zhenxuan also doubled its performance with a 100.22% return in the same year [1] - Li Jin has been managing these funds since March 2023, with a strong focus on growth sectors [1][2] Investment Strategy - Li Jin emphasizes the importance of identifying industries with significant demand expansion and rapid growth, focusing on areas where market efficiency is lacking [2] - The investment strategy has been heavily centered on artificial intelligence since March 2023, despite initial market skepticism [2] - Li Jin's research has led to a tactical adjustment in Q3 2025, where he reduced exposure to new consumption and innovative pharmaceuticals due to overvaluation and unmet performance expectations [3] Market Outlook - For 2026, Li Jin anticipates a shift in economic growth drivers from monetary easing to credit expansion, which will support the recovery of corporate profitability [5] - The supply-side optimization is expected to enhance corporate earnings, with a forecast of double-digit profit growth for A-shares in 2026 [5] - Chinese companies are increasingly gaining global competitiveness through proactive international expansion, contributing to sustained growth in relevant sectors [6] - The overall valuation of A-shares remains reasonable, suggesting a transition from valuation-driven to a more balanced approach of fundamental and structural reform-driven growth [6] Future Focus - Li Jin plans to continue focusing on sectors with long-term growth potential, particularly in artificial intelligence, which is still in a critical "infrastructure" phase [6] - The demand for computing power and related technologies is expected to grow exponentially, with significant capital investments from internet companies [6] - Continuous attention will be given to opportunities in new energy, innovative pharmaceuticals, and new consumption sectors, aiming to identify high-quality growth leaders in emerging trends [6]

Group 1 - The core viewpoint of the article highlights the significant rise in Hong Kong's innovative drug concept stocks, indicating a positive trend in the sector [2] - Jingtai Holdings experienced a surge of over 6%, reflecting strong investor interest and confidence in the company [2] - Hengrui Medicine saw an increase of over 5%, suggesting robust performance and market positioning [2] - Four Seasons Pharmaceutical rose by more than 4%, indicating a favorable market response [2] - Innovent Biologics and WuXi Biologics both increased by over 3%, showcasing the overall strength of the innovative drug sector [2] - BeiGene's stock rose by over 2%, further contributing to the positive sentiment in the market [2]

Core Insights - The investment landscape for A-shares in 2026 is shifting, with a focus on both emerging technologies like AI and quantum technology, and the recovery of traditional industries, indicating a potential for strategic investments in both areas [1] Group 1: Investment Strategies - Starstone Investment anticipates a structural convergence in the market, with a focus on high-growth sectors such as AI, innovative pharmaceuticals, and military technology, alongside traditional industries like transportation and real estate [1] - Chongyang Investment maintains a positive outlook for 2026 but advises investors to temper return expectations, emphasizing a defensive strategy while seeking opportunities in underappreciated sectors like consumer goods and real estate [2] - Kangmand Capital identifies a dual strategy focusing on "growth horses" in the AI sector and "steady horses" in industries experiencing rapid profit recovery, driven by the current economic cycle [3] - Qinghequan Capital highlights the resilience of China's manufacturing sector and anticipates a shift towards profit-driven investments, focusing on strategic resources and consumer goods [4] - Xuanyuan Investment outlines four key judgments for 2026, emphasizing a market still on an upward trajectory but with a different rhythm, and identifying opportunities in midstream manufacturing and emerging industries [5][6] - Xiangju Capital expresses confidence in a favorable macro environment for stock investments in 2026, while suggesting a need to lower return expectations compared to 2025 [7] Group 2: Sector Focus - Key sectors of interest include AI, innovative pharmaceuticals, and advanced manufacturing, with a particular emphasis on industries that have been historically overlooked [2][3] - Strategic resources such as copper, aluminum, and coal are expected to be focal points for investment, alongside global capital goods like machinery and power equipment [4] - The emphasis on expanding domestic demand highlights opportunities in service-oriented sectors, including cultural tourism and elder care [6]

Core Insights - The inclusion of three innovative drugs developed by Kelun-Botai in the national medical insurance directory signifies a successful transformation of innovation into accessible healthcare for patients, reflecting a collaborative effort between national policies and corporate innovation [1][3][5] Group 1: Product Development and Market Entry - Kelun-Botai's LuKangSatuzumab (佳泰莱) is the first domestically developed ADC drug approved for treating advanced triple-negative breast cancer (TNBC), marking a significant advancement in treatment options for patients who have undergone at least two prior therapies [2][4] - The company’s other two drugs, Westuzumab N01 and Tagolizumab, target colorectal cancer and nasopharyngeal carcinoma, respectively, and are also included in the new insurance directory, promoting affordable access to treatment [4][5] Group 2: Addressing Clinical Needs - The introduction of LuKangSatuzumab addresses a critical gap in treatment options for patients with late-stage TNBC and EGFR mutation-positive non-small cell lung cancer (NSCLC), providing new hope for those with limited alternatives [2][3] - The innovative drugs not only fill existing treatment voids but also aim to alleviate the financial burden on patients by being included in the insurance reimbursement system [3][6] Group 3: Economic and Social Impact - The pricing strategy for these innovative drugs is designed to be more affordable, preventing patients from falling into poverty due to medical expenses, which reflects the company's commitment to patient-centered care [4][5] - The recent adjustments in the national medical insurance directory demonstrate a strong support for innovative drugs, with 111 new drugs added, 97.4% of which are newly launched within the last five years, indicating a focus on enhancing patient access to cutting-edge treatments [5][6] Group 4: Sustainable Innovation Ecosystem - The collaboration between the government and pharmaceutical companies aims to create a sustainable innovation ecosystem, ensuring that clinical needs are met while providing reasonable returns for genuine innovation [6][7] - This dual engagement fosters a clearer direction for research and development, emphasizing the importance of addressing unmet clinical needs rather than merely replicating existing treatments [6][7]

Core Viewpoint - The inclusion of the long-acting growth hormone, Jinpei, in the national medical insurance directory marks a significant milestone in the treatment of children's growth disorders in China, aiming to improve treatment rates and reduce financial burdens on families [1][3][7]. Group 1: Market Opportunity - Approximately 7 million children in China suffer from short stature, with a treatment rate of less than 5%, compared to 20%-30% in developed countries [2]. - The new medical insurance policy is expected to enhance the treatment rate for short stature by making long-acting growth hormone more accessible and affordable [2][3]. Group 2: Economic Impact - The annual treatment cost for a 30 kg child using Jinpei will decrease from approximately 120,000 yuan to 30,000 yuan after being included in the insurance [3]. - The long-acting formulation reduces the injection frequency from daily to weekly, significantly improving patient compliance and reducing treatment-related pain [3][5]. Group 3: Innovation and Development - Jinpei is the first PEG long-acting growth hormone globally, representing a breakthrough in the treatment of growth hormone deficiency [1][4]. - The product has been validated through over 150,000 patient clinical applications, demonstrating its safety and efficacy [5][6]. Group 4: Competitive Landscape - The entry of Jinpei into the insurance directory is expected to reshape the pediatric pharmaceutical market, enhancing the company's competitive position by providing a comprehensive product line [7][8]. - The official endorsement from the insurance directory is likely to alleviate parental concerns regarding the safety of growth hormone treatments, potentially increasing patient conversion rates [7][8]. Group 5: Future Prospects - The successful integration of Jinpei into the medical insurance system is anticipated to pave the way for further pediatric product launches by the company, enhancing its brand trust among healthcare providers and patients [8][9]. - The trajectory of the company reflects the broader innovation and upgrade trends within China's pharmaceutical industry, indicating a shift towards more accessible and effective treatments for pediatric patients [9].

此次三款药物纳入医保，不仅降低了以往高昂的治疗成本，更通过医保报销机制切实缓解患者的经济压 力，让这份"生命希望"真正变得触手可及。针对临床未满足的需求和治疗费用的降低，科伦博泰总经理 兼首席执行官葛均友博士表示，"当你知道自己的创新研究成果可能改变一个疾病领域的治疗格局，能 够填补目前治疗不了的领域时，那种使命感超越了任何商业考量。虽然医保目录内已有同类治疗产品， 但我们愿意以更加亲民的价格推进国产替代，防止患者因病致贫、因病返贫。" 智通财经APP了解到，1月1日，《国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创 新药品目录(2025年)》正式落地实施。在这份新目录中，科伦博泰生物-B(06990)自主研发的芦康沙妥珠 单抗(佳泰莱)、西妥昔单抗N01(达泰莱)与塔戈利单抗(科泰莱)三款创新药物成功跻身其中。 据悉，对于晚期三阴性乳腺癌患者及EGFR-TKI治疗失败的非小细胞肺癌患者而言，传统治疗手段往往 收效甚微。而作为科伦博泰自主研发的国内首个获完全批准上市的国产ADC(抗体药物偶联物)，芦康沙 妥珠单抗于2024年11月正式获批，用于治疗既往至少接受过2种系统治疗(其中至少1种针对晚期 ...

Summary of Deyuan Pharmaceutical Conference Call Company Overview - Deyuan Pharmaceutical focuses on the development, production, and sales of drugs for metabolic diseases, particularly diabetes and hypertension [2][11]. Key Points Industry and Market Dynamics - The global diabetes market is projected to grow from USD 64.1 billion in 2024 to USD 76.1 billion by 2029, with China expected to have 174 million diabetes patients by 2045 [15]. - The hypertension market is also expanding, with over 300 million patients in China, indicating a significant demand for antihypertensive medications [15]. - The Chinese generic drug market has seen rapid growth, with a market size of CNY 586.9 billion in 2022, expected to grow significantly due to patent expirations and supportive policies [19]. Financial Performance - In the first three quarters of 2025, Deyuan achieved a revenue of CNY 796 million, a year-on-year increase of 21.88%, and a net profit of CNY 159 million, up 37.86% [3][13]. - The gross margin improved to 84.10% in 2025, up from 80.07% in 2022, driven by new product approvals [8][9]. - The company expects net profit to reach CNY 1.9 billion in 2025, CNY 2.14 billion in 2026, and potentially CNY 2.4-2.5 billion in 2027, with a growth rate of 10%-15% [2][10]. Product Development and Pipeline - Deyuan plans to launch 50 generic drug varieties by 2027, each contributing an average of CNY 50 million in revenue, targeting a sales scale of over CNY 2 billion for the generic drug segment [2][4]. - Key innovative drugs in development include DYX 116 (a GLP-1 triple agonist for diabetes and weight loss) and DYX 216 (for resistant hypertension), with DYX 116 expected to complete Phase I clinical trials by the end of 2025 [2][4][5]. Competitive Advantages - Deyuan has a strong product line in diabetes and hypertension, with a unique market position for its first generic drug, Bo Ka Qing [14]. - The company benefits from the collective procurement policy, which has allowed it to rapidly increase sales and market share while optimizing cost structures [16][17]. Research and Development - Deyuan invests significantly in R&D, with plans to obtain one new drug IND annually. The R&D expenses for 2024 were CNY 117 million, accounting for approximately 13% of revenue [20][9]. - The company has over 30 projects in development, including collaborations with research institutions to develop new diabetes treatments [20][6]. Future Outlook - Deyuan's strategy includes expanding its product offerings in diabetes and hypertension, with expectations of 8-10 new approvals annually [24]. - The success of innovative drugs like DYX 116 and DYX 216 could significantly enhance the company's competitive position and valuation [24]. Risks and Challenges - Potential risks include the failure of innovative drug development and the impact of collective procurement on generic drug pricing [10][16]. Conclusion Deyuan Pharmaceutical is well-positioned in the growing markets for diabetes and hypertension treatments, with a robust pipeline of generic and innovative drugs. The company's financial performance and strategic initiatives suggest a positive outlook for future growth and market expansion.